ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Cross Above 50-Day Moving Average of $60.85

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) shares passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $60.85 and traded as high as $66.85. ProShares Ultra Nasdaq Biotechnology shares last traded at $65.92, with a volume of 24,320 shares.

ProShares Ultra Nasdaq Biotechnology Price Performance

The stock has a 50 day moving average of $61.17 and a two-hundred day moving average of $57.76.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 3rd. Shareholders of record on Wednesday, June 26th were given a dividend of $0.2648 per share. The ex-dividend date of this dividend was Wednesday, June 26th. This is a positive change from ProShares Ultra Nasdaq Biotechnology’s previous quarterly dividend of $0.04. This represents a $1.06 dividend on an annualized basis and a yield of 1.67%.

Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of institutional investors have recently bought and sold shares of BIB. Toth Financial Advisory Corp lifted its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 17.3% during the 4th quarter. Toth Financial Advisory Corp now owns 11,241 shares of the exchange traded fund’s stock valued at $641,000 after buying an additional 1,655 shares during the last quarter. Simplex Trading LLC lifted its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 5,408.9% during the 4th quarter. Simplex Trading LLC now owns 2,479 shares of the exchange traded fund’s stock valued at $141,000 after buying an additional 2,434 shares during the last quarter. Clarity Capital Partners LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter valued at about $201,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter worth approximately $288,000. Finally, Westwood Wealth Management acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the 1st quarter worth approximately $575,000.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.